Stock of The Day: Could Amarin Corporation plc (ADR) Gain Strenght? The Stock Reaches Yearly Low

Stock of The Day: Could Amarin Corporation plc (ADR) Gain Strenght? The Stock Reaches Yearly Low

The stock of Amarin Corporation plc (ADR) (NASDAQ:AMRN) is a huge mover today! The stock last traded at $2.99 per share. It is down 84.57% since March 11, 2016 and is uptrending. It has outperformed by 79.11% the S&P500.
The move comes after 5 months negative chart setup for the $624.36M company. It was reported on Oct, 14 by We have $2.78 PT which if reached, will make NASDAQ:AMRN worth $43.71 million less.

Analysts await Amarin Corporation plc (ADR) (NASDAQ:AMRN) to report earnings on November, 2. They expect $-0.14 earnings per share, up 22.22% or $0.04 from last year’s $-0.18 per share. After $-0.11 actual earnings per share reported by Amarin Corporation plc (ADR) for the previous quarter, Wall Street now forecasts 27.27% negative EPS growth.

Amarin Corporation plc (ADR) (NASDAQ:AMRN) Ratings Coverage

Out of 2 analysts covering Amarin Corp (NASDAQ:AMRN), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Amarin Corp has been the topic of 2 analyst reports since May 12, 2016 according to StockzIntelligence Inc. The rating was initiated by Cantor Fitzgerald on Wednesday, October 5 with “Buy”. The stock of Amarin Corporation plc (ADR) (NASDAQ:AMRN) earned “Buy” rating by Jefferies on Thursday, May 12.

According to Zacks Investment Research, “Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies.”

Insitutional Activity: The institutional sentiment increased to 1.04 in Q2 2016. Its up 0.41, from 0.63 in 2016Q1. The ratio improved, as 9 funds sold all Amarin Corporation plc (ADR) shares owned while 17 reduced positions. 7 funds bought stakes while 20 increased positions. They now own 30.07 million shares or 19.93% less from 37.56 million shares in 2016Q1.
Two Sigma Securities Ltd Liability Com last reported 0.01% of its portfolio in the stock. Ameriprise Fin last reported 0% of its portfolio in the stock. Clearbridge Ltd Company has invested 0.12% of its portfolio in Amarin Corporation plc (ADR) (NASDAQ:AMRN). Vsr Financial Svcs holds 0.01% or 22,200 shares in its portfolio. Next Grp Incorporated Incorporated last reported 0% of its portfolio in the stock. Fmr Lc reported 2.04M shares or 0% of all its holdings. Orbimed Advisors Llc has invested 0.01% of its portfolio in Amarin Corporation plc (ADR) (NASDAQ:AMRN). Cetera Lc owns 13,200 shares or 0% of their US portfolio. Credit Suisse Ag has 27,942 shares for 0% of their US portfolio. Geode Cap Lc has 0% invested in the company for 79,241 shares. Moreover, Barclays Public Ltd Company has 0% invested in Amarin Corporation plc (ADR) (NASDAQ:AMRN) for 27,216 shares. Pnc Fincl Serv, a Pennsylvania-based fund reported 25,600 shares. The New York-based Art Advsr Ltd Liability Com has invested 0.01% in Amarin Corporation plc (ADR) (NASDAQ:AMRN). Court Place Advisors Limited Liability Corporation last reported 0.01% of its portfolio in the stock. Balyasny Asset Management Ltd Liability Co reported 1.25 million shares or 0.02% of all its holdings.

Another recent and important Amarin Corporation plc (ADR) (NASDAQ:AMRN) news was published by which published an article titled: “Why Amarin Corporation plc (ADR) is Moving Higher Today” on August 07, 2015.

AMRN Company Profile

Amarin Corporation plc, incorporated on March 1, 1989, is a biopharmaceutical firm with activities in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. The Firm operates in the business segment of development and commercialization of Vascepa. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its Distributors, that in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers. The Firm markets Vascepa in the United States through its sales force of approximately 150 sales professionals, including sales representatives and their managers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment